Skip to main content

Table 1 Baseline clinical and pathological characteristics of patients using ypTNM stage or pTNM stage in Peking University Cancer Hospital & Institute, 2007–2015 (n = 1441)

From: Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: a propensity score-matched analysis

Characteristics Total (N = 1441) ypTNM (N = 449) pTNM (N = 992) P value*
Age (μ ± sd) 59.2 ± 11.4 59.3 ± 10.2 59.1 ± 11.9 0.69
Female 397 (27.55%) 102 (22.72%) 295 (29.74%) 0.006
Family history of cancer (yes) 328 (22.76%) 81 (18.04%) 247 (24.9%) 0.004
BMI (μ ± sd, kg/m2) 23.5 ± 3.4 23.4 ± 3.3 23.5 ± 3.5 0.71
ECOG     0.08
 0 928 (64.4%) 290 (64.59%) 638 (64.31%)  
 1 419 (29.08%) 139 (30.96%) 280 (28.23%)  
 2 94 (6.52%) 20 (4.45%) 74 (7.46%)  
Tumor location     < 0.001
 Upper 393 (27.27%) 166 (36.97%) 227 (22.88%)  
 Middle 212 (14.71%) 59 (13.14%) 153 (15.42%)  
 Low 784 (54.41%) 195 (43.43%) 589 (59.38%)  
 Whole 52 (3.61%) 29 (6.46%) 23 (2.32%)  
Short diameter (μ ± sd, in cm) 2.9 ± 2.1 3.1 ± 2.4 2.9 ± 2.0 0.21
Long diameter (μ ± sd, in cm) 4.2 ± 2.8 4.5 ± 3.1 4.0 ± 2.6 0.035
Pathological type     < 0.001
 Adenocarcinoma 1089 (75.57%) 356 (79.29%) 733 (73.89%)  
 Signet ring cell carcinomaa 290 (20.12%) 67 (14.92%) 223 (22.48%)  
 Mucinous adenocarcinomab 62 (4.3%) 26 (5.79%) 36 (3.63%)  
Differentiation grade     0.029
 Well 159 (11.03%) 36 (8.02%) 123 (12.4%)  
 Moderate 666 (46.22%) 206 (45.88%) 460 (46.37%)  
 Poor 616 (42.75%) 207 (46.1%) 409 (41.23%)  
T stage     < 0.001
 T1 296 (20.54%) 35 (7.8%) 261 (26.31%)  
 T2 238 (16.52%) 68 (15.14%) 170 (17.14%)  
 T3 216 (14.99%) 66 (14.7%) 150 (15.12%)  
 T4 691 (47.95%) 280 (62.36%) 411 (41.43%)  
N stage     0.002
 N0 606 (42.05%) 157 (34.97%) 449 (45.26%)  
 N1 249 (17.28%) 94 (20.94%) 155 (15.63%)  
 N2 234 (16.24%) 84 (18.71%) 150 (15.12%)  
 N3a 224 (15.54%) 67 (14.92%) 157 (15.83%)  
 N3b 128 (8.88%) 47 (10.47%) 81 (8.17%)  
TNM stage     < 0.001
 IA 261 (18.11%) 25 (5.57%) 236 (23.79%)  
 IB 159 (11.03%) 43 (9.58%) 116 (11.69%)  
 IIA 110 (7.63%) 30 (6.68%) 80 (8.06%)  
 IIB 227 (15.75%) 102 (22.72%) 125 (12.6%)  
 IIIA 185 (12.84%) 76 (16.93%) 109 (10.99%)  
 IIIB 237 (16.45%) 85 (18.93%) 152 (15.32%)  
 IIIC 262 (18.18%) 88 (19.6%) 174 (17.54%)  
Vascular cancer embolus (yes) 876 (60.79%) 291 (64.81%) 585 (58.97%) 0.035
Hospital stay (μ ± sd, in days) 14.2 ± 13.8 14.6 ± 16.8 13.9 ± 11.9 0.11
Operative time (μ ± sd, in min) 206.2 ± 64.4 212.1 ± 63.6 203.6 ± 64.7 0.003
Blood loss (μ ± sd, in ml) 150.6 ± 210.7 175.2 ± 324.6 139.5 ± 128.4 < 0.001
Gastrectomy type     < 0.001
 Laparoscopicc 186 (12.91%) 24 (5.35%) 162 (16.33%)  
 Open 1255 (87.09%) 425 (94.65%) 830 (83.67%)  
Resection range     < 0.001
 Total 496 (34.42%) 210 (46.77%) 286 (28.83%)  
 Distal 785 (54.48%) 171 (38.08%) 614 (61.9%)  
 Proximal 141 (9.78%) 55 (12.25%) 86 (8.67%)  
 Thoraticabdominal joint 19 (1.32%) 13 (2.9%) 6 (0.6%)  
 Multi-organ excision (yes) 80 (5.55%) 36 (8.02%) 44 (4.44%) 0.006
Reconstruction approach     < 0.001
 Billroth II 342 (23.73%) 77 (17.15%) 265 (26.71%)  
 Billroth I 412 (28.59%) 88 (19.6%) 324 (32.66%)  
 Roux-en-Y 369 (25.61%) 138 (30.73%) 231 (23.29%)  
 Jejunal interposition 165 (11.45%) 83 (18.49%) 82 (8.27%)  
 Other 153 (10.62%) 63 (14.03%) 90 (9.07%)  
ASA     0.21
 1 205 (14.23%) 60 (13.36%) 145 (14.62%)  
 2 969 (67.24%) 316 (70.38%) 653 (65.83%)  
 3 267 (18.53%) 73 (16.26%) 194 (19.56%)  
N of lymph nodes dissected (μ ± sd) 31.0 ± 12.0 32.0 ± 12.2 30.5 ± 11.9 0.06
N of lymph nodes metastasis (μ ± sd) 4.7 ± 7.5 5.2 ± 8.0 4.4 ± 7.2 0.004
  1. ainclude adenocarcinoma with signet ring
  2. binclude adenocarcinoma with mucinous adenocarcinoma, mucinous adenocarcinoma with signet ring
  3. cinclude total laparoscopic and laparoscopic-assisted gastrectomy
  4. *Mann-Whitney U test was used for all continuous variables